This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (24)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Mortimer M. Bortin, MD; Alfred A. Rimm, PhD

JAMA. 1978;240(12):1245-1252.

Abstract
Fifty-seven patients with end-stage acute myeloblastic leukemia (AML) received a total of 65 bone marrow transplants between 1968 and 1976. Marrow from HLA genotypically identical allogeneic donors was administered to 32 patients, 13 received marrow from HLA-incompatible donors, donorrecipient HLA compatibility was undetermined for eight patients, and identical twins were marrow donors for four patients. None of the patients in the three latter groups survived beyond 9.4 months after transplantation. Two patients treated with marrow transplants from HLA-compatible donors currently are alive and free of leukemia with functioning grafts 13 and 38 months after transplantation. The 32 patients in the Registry series who received marrow from HLA-compatible donors were compared with a similar series of 46 patients in Seattle. Data for these 78 patients were pooled and analyzed for pretransplant factors that might have prognostic value. Patients with end-stage AML had approximately a 10% chance of surviving 20 months after high-dose chemoradiotherapy plus marrow transplantation. Patients younger than 21 years had a higher six-month survival rate than patients older than 30 years. Patients in the Registry series who received transplants with HLA-compatible marrow within eight months of diagnosis had a higher survival experience than patients who received transplants later.

(JAMA 240:1245-1252, 1978)

Footnotes
Ninth report from the International Bone Marrow Transplant Registry, Milwaukee.

Reprint requests and requests for the appendix to International Bone Marrow Transplant Registry, 950 N 12th St, Milwaukee, WI 53233 (Dr Bortin). The appendix consists of nine tables containing pretransplant, transplant, and posttransplant data from individual patients in the Registry series plus a comparison of pretransplant and posttransplant data from patients in the Registry and Seattle series who were treated with marrow transplants from HLA-compatible donors.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Bone Marrow Transplantation for Acute Myelogenous Leukemia: Factors Associated With Early Mortality
Bortin et al.
JAMA 1983;249:1166-1175.
ABSTRACT  

Allogeneic Bone Marrow Transplantation for 144 Patients With Severe Aplastic Anemia
Bortin et al.
JAMA 1981;245:1132-1139.
ABSTRACT  

Bone Marrow Transplantation for Acute Leukemia
Bortin and Rimm
JAMA 1979;242:1970-1970.
ABSTRACT